Form 4: Theravance Director Sells Shares, Exercises Options

Theravance Biopharma Director Eran Broshy sold 59,000 ordinary shares and exercised 14,000 stock options on November 11, 2025, under a pre-arranged trading plan.

Summary

• Eran Broshy, a Director of Theravance Biopharma, Inc. (TBPH), reported transactions on November 11, 2025.
• Mr. Broshy sold a total of 59,000 Ordinary Shares in multiple transactions.
• The sales included 29,500 shares at $18.5 per share and 15,500 shares at $17 per share.
• An additional 14,000 Ordinary Shares were sold at $18.5 per share, which were acquired through the exercise of stock options on the same day.
• Mr. Broshy exercised 14,000 Share Options at an exercise price of $10.15 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2024.
• Following these transactions, Mr. Broshy beneficially owns 46,204 Ordinary Shares directly and 107,878 Share Options directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director reducing their direct shareholding, even though it was part of a pre-arranged plan. The exercise of options to sell is a common practice for liquidity and diversification, which mitigates a stronger negative interpretation.

Positives

• The director realized value from vested stock options, indicating a successful personal investment outcome.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to immediate company news.

Negatives

• The director's direct ownership of ordinary shares decreased by 59,000 shares, which could be perceived by some investors as a reduction in insider confidence.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide specific industry context or relate to broader industry trends beyond the general practice of executives managing their equity compensation.

Stakeholder Impact

• Shareholders may monitor insider transactions for signals about management's confidence in the company's future prospects. A reduction in direct ownership, even if planned, could be viewed with caution.

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Stock Options, Share Sale, Director, Eran Broshy, 10b5-1 Plan